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ABSTRACT
The p53-family member p73 plays a role in various
cellular signaling pathways during development and
growth control and it can have tumor suppressor
properties. Several isoforms of p73 exist with con-
siderable differences in their function. Whereas the
functions of the N-terminal isoforms (TA and "Np73)
and their opposing pro- and antiapoptotic roles
have become evident, the functional differences of
the distinct C-terminal splice forms of TAp73 have
remained unclear. Here, we characterized the global
genomic binding sites for TAp73a and TAp73b by
chromatin immunoprecipitation sequencing as well
as the transcriptional responses by performing RNA
sequencing. We identified a specific p73 consensus
binding motif and found a strong enrichment of AP1
motifs in close proximity to binding sites for TAp73a.
These AP1 motif-containing target genes are select-
ively upregulated by TAp73a, while their mRNA ex-
pression is repressed upon TAp73b induction. We
show that their expression is dependent on en-
dogenous c-Jun and that recruitment of c-Jun to
the respective AP1 sites was impaired upon
TAp73b expression, in part due to downregulation
of c-Jun. Several of these AP1-site containing
TAp73a-induced genes impinge on apoptosis induc-
tion, suggesting an underlying molecular mechan-
ism for the observed functional differences
between TAp73a and TAp73b.
INTRODUCTION
The transcription factors of the p53-family, p53, p63 and
p73, maintain the balance between cell survival and
induction of apoptosis during development, growth,
differentiation and cellular stress. The members of
the p53-family thereby display common as well as
speciﬁc functions (1). They determine the cellular fate
dependent on the family member and isoform expressed
in a speciﬁc tissue. The p73 protein exists in multiple
isoforms due to different promoter usage at the
N-terminus and to C-terminal splice events. The Np73
isoforms that are derived from an internal promoter,
antagonize the growth suppressing, pro-apoptotic func-
tions of p53 and of the full length TAp73 isoforms in
a dominant negative way by competing for the re-
spective binding sites (2). Overexpression of Np73
isoforms is found in several tumors (3,4) whereas
mutations in the p73 gene are rarely found in human
cancers (5).
Under certain conditions, p53 is unable to induce apop-
tosis in the absence of p73 or p63 (6). Furthermore, mice
heterozygous for p53/p73 show a higher tumor burden
compared to p53 heterozygous mice (7). Although
complete knockout of the p73 gene in mice mainly leads
to developmental defects (8), the knockdown of only the
TA isoforms induces genomic instability, thus showing
tumor suppressor activities of TAp73 (9). TAp73
isoforms have been reported to play a role in DNA
damage pathways, since p73 is activated by ionizing
irradiation and cisplatin through c-Abl, thereby
inducing apoptosis (10–12). Furthermore, TAp73
isoforms are upregulated by different mechanisms
through chemotherapeutic drug induced DNA damage
(13,14).
The transcriptional function of p73 is complex because
of the plethora of p73 isoforms, which have varying tran-
scriptional activity toward target genes. In addition to
shared target sites, the p53-family members differ in
their ability to transactivate common target genes like
p21 (15) or Bax (16,17). Some genes are only induced by
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 speciﬁc isoforms, like p57/kip2 by p73b but not by p73a or
by p53 (18).
Besides its function as a pro-apoptotic protein, several
reports have also described an inhibition of apoptosis or a
support of growth by TAp73 in certain cell lines under
speciﬁc conditions (19,20). It has been shown that a cross-
talk between the transcription factor c-Jun and p73 regu-
lates growth and that c-Jun enhances the function of p73
(21,22). However, the exact molecular mechanism of this
crosstalk remains unknown.
C-Jun is a member of the AP1 family of heterodimeric
transcription factors, regulating growth and apoptosis de-
pending on the cellular environment and on the compos-
ition of the respective dimer (23). Dimers containing c-Jun
mainly promote growth via G1-progression through the
transactivation of Cyclin D1 (24). The fact that a c-Jun
null mutation is embryonically lethal and causes retarded
growth of cultured cells underscores the importance of
c-Jun for cellular growth (25). AP1 dimers can also
protect cells from UV-mediated apoptosis by negatively
regulating p53 (26) and c-Jun is also required for
re-entry of cells into cell cycle after UV-induced p53
mediated growth arrest (27). Due to the complexity of
the many p73 isoforms and the varying composition of
the Jun/Fos dimers several different interactions between
p73 and Jun/Fos might be possible, probably with differ-
ent consequences for the cellular fate.
To gain insight into the molecular basis for the different
physiological function of TAp73a and TAp73b,w e
identiﬁed their binding sites by chromatin immunopreci-
pitations (ChIPs) coupled with deep sequencing
(ChIP-seq) and global expression analysis using RNA
sequencing (RNA-seq). This revealed that the two
TAp73 isoforms bind to both shared and isoform-speciﬁc
target sites and distinctly transactivate target genes. We
uncovered a p73-consensus motif that is present in a large
fraction of the p73 binding sites. The binding sites of
TAp73a but not those of TAp73b showed an overrepre-
sentation of AP1 binding sites to which c-Jun can bind
simultaneously with TAp73a. The binding of c-Jun to
DNA is decreased upon TAp73b expression, which
reduces the mRNA and protein levels of c-Jun. The ex-
pression of distinct target genes with an AP1 site close to
TAp73a binding sites depends on c-Jun and they can in-
ﬂuence apoptosis induction by TAp73a, possibly explain-
ing the different physiological responses mediated by the
respective TAp73 isoforms.
MATERIAL AND METHODS
Cell culture conditions
The human MDA-MB231-, HCT116-, HEK293 cell lines
and the osteosarcoma Saos2 (parental cells or cell lines
with inducible p53, TAp73a or TAp73b) (28) were main-
tained in Dulbecco modiﬁed Eagle medium supplemented
with 10% fetal calf serum at 37 C. Expression of p53,
TAp73a or TAp73b in stably transfected cells was
induced with 0.5mg doxycycline (for TAp73a) or 2.0mg
doxycyclin (for TAp73b and p53). Transfections were per-
formed using the calcium phosphate precipitation method
(BES). Transient knockdown of IL1RAP and NEDD4L
was achieved by using Dharmacon ON-TARGETplus
siRNAs, according to manufacturers manual. Lentiviral
transduction was used to deliver pLKO-siRNA constructs
for the knockdown of c-Jun and p73 (Sigma), while
pLKO-siRNA targeting Luciferase served as a control.
Cell cycle analysis
Saos2 parental cells and Saos cell lines inducible for
TAp73a, TAp73b or p53 were induced for 24h or 48h,
prior to harvest. All cells were collected, resuspended in
PBS containing 1% FCS and ﬁxed in ethanol overnight at
4 C. DNA content was stained with propidium iodide
(Sigma) for 30min at room temperature and analyzed by
ﬂow cytometry (Becton Dickinson FACScan). The data
were analyzed using CellQuest Pro software.
Western blot analysis
Whole cell extract was harvested in 2 SDS sample
buffer, 4 sample buffer was added to aliquots of chro-
matin samples (see below for preparation of chromatin),
both types of samples were boiled and proteins were
separated by SDS–PAGE. After blotting, the following
antibodies were used to detect proteins: BL906 (anti-p73;
Abcam), DO1 (anti-p53; BD PharMingen), ab13487
(anti-active Caspase3; Abcam), SC45-X (anti-cJun;
SantaCruz Biotechnology), SL30 (anti-TATA-box
Binding Protein; anti-TBP), M2 (anti-FLAG; Sigma).
Secondary antibodies used were either rabbit–anti-mouse
or swine–anti-rabbit conjugated to HRP (Dako).
ChIP
ChIP was basically done as described by Denissov et al.
(29). To immunoprecipitate p53, DO1 antibody (BD
PharMingen) was used and BL906 (Abcam) was used
for p73. Immunoprecipitation of c-Jun was done with an
anti-c-Jun antibody (Upstate). Real-time qPCR was per-
formed using the SYBR Green mix (Biorad) with the
MyIQ machine (Biorad). Primers are listed in
Supplemental Table S5.
Prior to the Re-ChIP, p73-antibody (BL906) or
c-Jun-antibody (Upstate) was crosslinked to protein-A/
G-beads (SantaCruz) using 20mM dimethylpimelimidate
(pH: 8.5). The chromatin complexes from the ﬁrst ChIP
were eluted in 50ml of elution buffer and the SDS concen-
tration was adjusted with 5 incubation buffer without
SDS to 0.15% in the second ChIP-reaction. The
Re-ChIP included an unspeciﬁc or a beads only control,
respectively, to allow an estimation of leakage and
antibody carryover from the ﬁrst ChIP.
RNA isolation and RT–PCR
Total RNA was extracted using the RNeasy Mini Kit
according to protocol (Qiagen). For cDNA synthesis
retrotranscription was performed using 1mgo f
RNA with random hexamer primers, dNTPs, DTT,
buffer and Superscript Retrotranscriptase (Invitrogen).
2 Nucleic AcidsResearch, 2011
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 The cDNA was analyzed by real-time qPCR using a
MyIQ machine (Biorad). Primers are listed in
Supplemental Table S5.
RNA sequencing
To prepare samples for RNA-seq 100mg of total RNA
were subjected to polyA-selection with Oligotex Kit ac-
cording to protocol (Qiagen). Fragmentation of 100ng
polyA-selected mRNA was done for 105s at 94 Ci n
1 fragmentation buffer (40mM Tris acetate, pH 8.2;
100mM potassium acetate; 30mM magnesium acetate).
After puriﬁcation with RNeasy Mini Kit, according to
protocol (Qiagen) ﬁrst strand cDNA synthesis was per-
formed with random hexamer primers, dNTPs, DTT,
buffer and Superscript Retrotranscriptase (Invitrogen).
Second strand synthesis was done with Escherichia coli
DNA polymerase, E.coli DNA ligase, dNTPs buffer and
RNAseH. After puriﬁcation with Minelute Reaction
Cleanup Kit (Qiagen), the obtained material was used to
prepare sequencing samples according to the manufactur-
ers protocol (Illumina).
Illumina high-throughput sequencing (ChIP-seq)
Sequencing samples were prepared according to the manu-
facturers protocol (Illumina). Shortly, adapted sequences
were linked to the generated ChIP, the library was size
selected (200–250bp) and ampliﬁed by PCR. Clustering
and 36-cycle sequencing were performed using an
Illumina Cluster Station and Genome Analyzer according
to the manufacturer’s instructions. Images acquired from
the Genome Analyzer were processed through the bundled
image analysis pipeline (Illumina). All 35bp sequence
reads were uniquely mapped to the human genome
(NCBI build 36.1, hg18) with zero or one mismatch
allowed using ELAND software (Illumina). For visualiza-
tion purposes, all reads were directionally extended to
200bp, and the number of overlapping sequence reads
was determined for each position in the genome,
averaged over a 10bp window and visualized in the
UCSC genome browser (http://genome.ucsc.edu).
ChIP-seq data analysis
Two biological replicates were sequenced for all ChIP
samples. To incorporate the different signal/background
ratios of the different biological replicates and generate
high-conﬁdence peaks, we called peaks on a set of
combined reads randomly sampled from each combin-
ation of two replicates. We randomly selected  7 million
reads from each TAp73a and each Tap73b replicate and 3
million from each p53 replicate. We combined these
randomly selected reads ( 14 million for both TAp73a
and TAp73b, 6 million for p53) and used this set as
input for MACS (30). Peaks were called using default par-
ameters (P-value threshold 1E-5), using a Saos2 input
DNA sample as control ( 14 million reads). This
random sampling procedure was repeated 10 times, and
only the peaks determined in every single analysis were
kept. Peaks were mapped to RefSeq genes, downloaded
from the UCSC Genome Browser, to determine genomic
location.
RNA-seq data analysis
Two biological replicates were sequenced for each sample.
Reads were mapped to the genome and all reads mapping
within RefSeq genes (downloaded from the UCSC
Genome Browser) were counted. The read counts per
gene per replicate were used as input for DEGseq (31).
This R package was used to call differentially regulated
genes using the MARS method, with default parameters.
All genes with a signiﬁcant change (FDR<0.001) and an
absolute log2 fold change of 1 were called as regulated.
Association strength
The continuous association strength per gene was
calculated as described in Ouyang et al. (32). The associ-
ation strength of gene i is calculated as the a weighted sum
of intensities of all of the peaks within 2 Mb of the gene,
according to the following formula:
ai ¼
X
k
gke dk=d0
where gk is the total normalized number of reads aligned
of the kth binding site, dk is the distance (number of nu-
cleotides) between the TSS of gene i and the kth binding
site and d0 is 5000. The association strength values are
log2 transformed and quantile normalized.
Motif analysis
The location and score of the p53 motif within the 200bp
peaks was determined using p53scan with default settings
(www.ncmls.nl/bioinfo/p53scan/) (28).
To determine the p73 motif three motif prediction tools
were run on the 200bp peaks: MotifSampler (33), Weeder
(34) and MDmodule (35). A set of 1000 sequences,
randomly selected from the highest 5000 peak sequences
was used as input to predict motifs. We used the ‘large’
analysis setting for Weeder, and MDmodule and
MotifSampler were used to predict 10 motifs for each of
the even widths between 6 and 20. The signiﬁcance of the
predicted motifs was determined by scanning the remain-
ing 80% of the 5000 highest peak sequences (4000 se-
quences) and two different backgrounds: a set of
random genomic sequences with a similar genomic distri-
bution as the peak sequences and a set of random se-
quences generated according to a 1st order Markov
model (similar dinucleotide distribution as the peak
sequences). P-values were calculated using the
hypergeometric distribution with the Benjamini–
Hochberg multiple testing correction. All motifs with a
P<0.001 and at least an absolute enrichment>1.5
compared to both backgrounds were determined as sig-
niﬁcant. The closest matching motif in the JASPAR
database (36) was determined using STAMP (37).
The p53scan algorithm was modiﬁed to use the best
p73-motif matrix found in the motif analysis, hereafter
referred to as p73scan. The positional weight matrices
(PWM) is included as Supplementary Table S4. All
p73scan analyses reported in this study were carried out
with a spacer length of 0.
Nucleic Acids Research, 2011 3
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 The AP1-motif analyses were carried out with the
pwmscan.py program included with p53scan, using the
best performing AP1 matrix identiﬁed in this study as
PWM. This matrix is provided as Supplementary
Table S4. As a threshold for the AP1 pwmscan.py 0.98
was used, to select for stringent matches.
Data availability
The data have been deposited in NCBI’s Gene Expression
Omnibus (38) and are accessible through GEO Series ac-
cession number GSE15780 (http://www.ncbi.nlm.nih
.gov/geo/query/acc.cgi?acc=GSE15780).
RESULTS
Physiological and molecular differences in the cellular
responses to TAp73a and TAp73b
The domain organization of the predominant TAp73a-
and TAp73b isoforms shows some similarity with the
related tumor suppressor p53, but the three proteins
differ completely in their C-terminus (Figure 1A). To
characterize their common and distinct functions, we
used isogenic Saos cell lines (28) to express TAp73a and
TAp73b at comparable protein levels as detected in whole
cell lysates as well as in the chromatin-bound fraction
(Figure 1B). As a comparison, the effect of p53 on
apoptosis induction was included. To quantify the
degree of cell death after induction of TAp73a, TAp73b
or p53, FACS analysis was performed and apoptosis was
measured as the sub-G1 cell population (Figure 1C).
Whereas in the parental Saos2 cells only a small propor-
tion of cells undergo programmed cell death, the induction
of TAp73a, TAp73b or p53 leads to an increase in
the apoptotic population. The levels of apoptosis
after TAp73a induction are rather modest. Upon
TAp73b induction, on the other hand, apoptosis levels
are three to eight times higher than in parental Saos2
cells, thus comparable to p53-induced cell death. Since
the different p53-family members displayed distinct
effects on the level of apoptosis induction, we examined
possible molecular causes for these differences. To analyze
the DNA binding capacities of the two p73 isoforms and
p53 we used ChIP followed by qPCR (ChIP-qPCR).
As shown in Figure 1D binding of p53 and both TAp73
isoforms is observed to the p21 and Mdm2 genes. It
is higher for TAp73b at the p21 and Mdm2 binding
sites than for TAp73a. Examining the transactivating
potential of these p73 isoforms and p53 shows that both
isoforms increase the level of p21 mRNA, with a much
stronger increase mediated by TAp73b (Figure 1E). The
mRNA level of Mdm2 is increased upon TAp73b and p53
expression, but not upon TAp73a expression in this cell
system (Figure 1E). Thus, induction of TAp73a and
TAp73b had different effects on the transcriptional acti-
vation of target genes as well as on the cellular apoptotic
response.
Global binding proﬁles reveal common as well as distinct
binding sites for TAp73a and TAp73b
To shed light on the molecular mechanisms for the differ-
ential cellular responses induced by the two TAp73
isoforms, we compared their DNA binding site repertoire
at a genome-wide scale, performing ChIP-seq of the
TAp73 isoforms as well as of p53 (two biological repli-
cates each). To validate the reproducibility of the data
sets, we compared the number of reads per peak
between two biological replicates and found a high correl-
ation (Supplementary Figure S1). Identifying binding sites
by peak calling on the combined data using MACS (30),
with an input DNA sample as background control,
resulted in 15293 peaks for TAp73a, 23505 peaks for
TAp73b and 9878 peaks for p53 (Table 1). We identiﬁed
genome wide binding sites that are shared by both p73
isoforms (10319 sites) or are preferential for either
TAp73a (4196 sites) or TAp73b (11849 sites) exempliﬁed
by the Mdm2, IL1RAP and APOD gene, respectively
(Figure 2A–C).
Comparing the binding sites of TAp73a, TAp73b and
p53, we found that a large portion of binding sites is
bound by all three proteins, but also that a considerable
number is preferably bound by only one of the three
proteins (Figure 2D). We found that 44% of the
TAp73b binding sites and 46% of the p53 binding sites,
respectively, overlap with TAp73a (Figure 2D). Thus,
while there are many target genes common between
TAp73a, TAp73b and p53, there are also isoform and
family member-speciﬁc binding sites, possibly mediating
the differential functions of TAp73a, TAp73b and p53.
To gain further insight into the characteristics of the
DNA binding sites, we analyzed their genomic distribu-
tion (Figure 2E). Both TAp73 isoforms show almost the
same genomic binding distribution being signiﬁcantly
enriched in promoter regions, compared to genomic back-
ground, but not as pronounced as the p53 binding sites
from which almost one third are found close to transcrip-
tional start sites.
Since we have identiﬁed global binding proﬁles for
TAp73a, TAp73b and p53 expressed in isogenic Saos
cell lines, we wanted to verify that these binding sites
could be physiological target sites of endogenous p73
and p53. Therefore, we have analyzed MDA-MB231-,
HEK293- and HCT116-cell lines, which express p53 and
p73 (Figure 3A, left), for p73- and p53-DNA binding and
compared it with the binding events in the different Saos
cells used before. Binding to the positive control p21
occurred in all cases (Figure 3A, right), while some
binding sites can be bound by p73 as well as p53 in
several different cell lines, e.g. binding sites close to the
FAS, DCP1B and GDF15 gene (Figure 3B). Furthermore,
we also identiﬁed target sites that are selectively bound by
p73 only in speciﬁc cell lines, such as the METT10D,
NDUFS2 and DEDD gene (Figure 3C). Thus, binding
sites originally identiﬁed in Saos cell lines can also be
found in cell lines expressing endogenously p73 or p53.
The isoform-speciﬁc occupancy appears to be cell type
dependent.
4 Nucleic AcidsResearch, 2011
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Figure 1. Differential physiological and molecular effects of TAp73a and TAp73b.( A) Domain structure of the p53-family members TAp73a,
TAp73b and p53. TA, transactivation domain; DBD, DNA-binding domain; OD, oligomerization domain; SAM, sterile a-motif; ID, inhibitory
domain. (B) Expression of TAp73a, TAp73b and p53 in Saos-inducible cell lines. Whole cell extracts or chromatin was harvested after 24h of
induction and protein levels were analyzed by western blot. (C) Induction of apoptosis. Saos cells expressing the indicated member of the p53-family
were induced for 24 or 48h, before the amount of cells in sub-G1 phase, as a measure for apoptotic induction, was counted using FACS. Error bars
indicate standard deviation (SD) derived from three independent experiments, asterisks indicate statistical signiﬁcance as shown by Student’s t-test
(P<0.05). (D) Differential binding of TAp73a and TAp73b to target genes, using p53 as a positive control. Saos TAp73- or p53-inducible cells were
induced for 24h before chromatin was isolated. Complexes of TAp73 or p53 and chromatin were precipitated and qPCR analysis was performed
with primers for the putative binding sites and enrichment is shown in fold over an unspeciﬁc control (myoglobin). SD results from three independent
experiments. (E) Expression changes upon induction of p53-family isoforms. RNA from Saos cells was harvested 24h after induction of the
respective family member. After cDNA synthesis qPCR was performed with the indicated primers and results were normalized against GAPDH
expression. The induction was calculated as fold over the normalized expression values from Saos2 parental cells. SD was calculated from three
independent experiments.
Table 1. ChIP-seq results
Replicate no. Uniquely mapped
reads (million)
Reads after
normalization
(million)
Number of
peaks
Genes with a
peak within 25kb
Saos control 1 14.82 14.82
Saos TAp73a 1 12.52 7.41 15293 5405
Saos TAp73a 2 13.77 7.41
Saos TAp73b 1 12.10 7.41 23505 6932
Saos TAp73b 2 13.08 7.41
Saos p53 1 5.53 3.00 9878 5665
Saos p53 2 14.71 3.00
Nucleic Acids Research, 2011 5
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 Isoform-speciﬁc transcriptional responses
Having identiﬁed genome wide binding sites for TAp73a,
TAp73b and p53, we were interested in the transcriptional
consequences of the induction of the three proteins and to
which extent the DNA binding and transcriptional
changes could be correlated. Therefore, we performed
global transcriptome analysis of TAp73a, TAp73b and
p53 expressing Saos cells using RNA-seq. Two biological
replicates were sequenced per cell line and the fold change
relative to the Saos2 parental control was calculated using
DEGseq (31). The two p73 isoforms show distinct expres-
sion signatures, with genes speciﬁcally regulated after in-
duction of TAp73a (485 genes) or TAp73b (575 genes), as
well as genes regulated in both cases (338 genes)
(Figure 4A and B). The previously reported, TAp73b-
speciﬁc target gene p57/Kip2/CDKN1C is also in our
Figure 2. Global binding site analysis of p53-family members. (A) Common binding site for TAp73a and TAp73b. The lower track displays the
location of the Mdm2 proto-oncogene in the UCSC genome browser. The upper track shows the binding site for TAp73a and the middle one the site
for TAp73b as determined by ChIP-seq using the Genome Analyzer (Illumina) and visualized with the UCSC genome browser. (B) Preferential
binding site for TAp73a. The lower track displays the location of the IL1RAP gene, the other tracks as described in ‘A’. (C) Preferential binding site
for TAp73b. The lower track displays the location of the APOD gene, the other tracks as described in ‘A’. (D) Overlap of target genes that were
determined by ChIP-seq for TAp73a, TAp73b and p53. (E) The genomic distribution of binding sites for TAp73a, TAp73b and p53 after ChIP-seq is
compared with the respective categories within the human genome. Locations of binding sites are divided in transcriptional start site (TSS) ﬂanking
region (5kb upstream of TSS+ﬁrst exon+ﬁrst intron), intragenic region (all exons and introns except ﬁrst),<25kb (peaks within 25kb of the next
annotated gene) and intergenic region (peaks>25kb away from any annotated gene).
6 Nucleic AcidsResearch, 2011
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 genome-wide RNA-seq data and is clearly induced only
upon TAp73b expression (Supplementary Figure S2A).
Two newly identiﬁed examples of isoform-speciﬁc regula-
tion are shown in Figure 4C and D: the SFN gene, spe-
ciﬁcally activated by TAp73a and the BGN gene,
speciﬁcally activated by TAp73b. Both genes are also dif-
ferentially bound by one of the p73 isoforms as seen in the
ChIP-seq data being in good agreement with the RNA-seq
data. The GHRL3 gene on the other hand showed binding
and activation by both isoforms (Figure 4E). The
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Figure 3. Validation of binding sites in other cell lines. (A) Expression of endogenous p73 and p53 in several human cell lines. Protein samples were
harvested from the different cell lines and stained against p73 or p53 as indicated (left). As a positive control for ChIP-qPCR in the respective cell
line, binding to the p21-promoter was examined (right). Error bars were derived from two independent experiments. (B) Binding of p73 and p53 to
target genes in several cell lines. ChIP-qPCR with a p73-antibody was performed in MDA-MB231, HEK293 and HCT116 cells or against p53 in
HCT116 and HEK293 cells. As a comparison, binding to the sites in the different Saos cells is shown. The indicated primers were used to calculate
the respective enrichment. Error bars were derived from two independent experiments. (C) Cell line speciﬁc binding to target genes. ChIP-qPCR was
performed as in ‘B’.
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Figure 4. Analysis of expression changes induced by TAp73 by RNA-Seq. (A) Differential transcriptional responses upon induction of TAp73a or
TAp73b. Upon 24h induction of TAp73a or TAp73b global expression proﬁles were obtained in duplicates using RNA-seq. The fold change relative
to Saos2 parental control was calculated using DEGseq (31) and differential gene expression of the two p73 isoforms was plotted. (B) Overlap of
expression-changing genes after induction of TAp73a, TAp73b or p53 as analyzed by RNA-seq. (C) Preferential binding of TAp73a results in speciﬁc
transcriptional induction of the SFN gene by TAp73a. The two upper tracks display the ChIP-seq-data from TAp73a or TAp73b, respectively.
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 differential transcriptional response observed was further
validated by RT–qPCR proving good agreement with the
RNA-seq results (Figure 4C–E, right).
The overlap between regulated genes and p73 binding
sites is highly signiﬁcant. Of the TAp73a upregulated
genes, 49% have a TAp73a binding site within 25kb
(P=3.08E-19), and 50% of the TAp73b upregulated
genes have a TAp73b binding site (P=3.56E-7)
(Table 2 and Supplementary Table S1). The relation
between binding and expression is visualized in
Figure 4F, which illustrates that differentially regulated
genes have a signiﬁcantly higher association strength
(32) than unregulated genes (TAp73a, P<2.2E-16;
TAp73b, P<2.2E-16).
Analyzing the functional annotation of bound and
regulated TAp73a and TAp73b target genes by GO
analysis using DAVID (39,40), we uncovered a plethora
of different physiological aspects that appear to be
regulated by TAp73a and TAp73b (Supplementary
Table S2). Most strikingly both isoforms regulate the ex-
pression of genes involved in different developmental
processes such as tissue development, cell differentiation
and development of speciﬁc anatomical structures.
Interestingly, in a KEGG pathway analysis (41) of
regulated target genes, the two p73 isoforms appear to
regulate different functional subgroups of genes, high-
lighting that the functions of TAp73a and TAp73b are
not merely overlapping, but also distinct (Supplementary
Table S2). The most prominent functional link of this
KEGG pathway analysis can be seen for TAp73a for me-
tastasis involved processes: TAp73a seems to induce target
genes that fall into several functional categories linked to
metastasis, such as focal adhesion, ECM-receptor inter-
action, cell communication and regulation of actin cyto-
skeleton. For TAp73b, on the other hand, the
p53-signalling pathway is the ﬁrst functional category
that appears in the KEGG pathway analysis. Thus, the
functional annotation analysis hints at common as well as
distinct functions of TAp73a and TAp73b during cellular
growth and development.
Characteristics of TAp73a and TAp73b binding sites
The distinct binding patterns of TAp73a and TAp73b as
well as their different transactivating potential led us to
analyze the binding sites with respect to their sequence
contents and properties. We used a comprehensive discov-
ery approach to predict motifs for the TAp73a as well as
the TAp73b binding sites. Three different motif prediction
tools (MDmodule, MotifSampler and Weeder) were
applied to the binding sites and resulting motifs were
tested for their signiﬁcance compared to a set of back-
ground sequences (see ‘Materials and Methods’ for
details). After inspection of the signiﬁcant motifs using
STAMP (37), we found the prevalent motif in both
TAp73 sets to be a p53-like motif, hereafter referred to
as the p73 consensus-binding motif (Figure 5A and
Supplementary Table S3). We tested the performance of
the discovered motifs by comparing the area under curve
(AUC) of the receiver operator curve (ROC), which sum-
marizes the trade-off between sensitivity and speciﬁcity
when varying the motif score threshold. There was no
clear difference in the PWM of the best performing
TAp73a and TAp73b motif, but slight differences when
comparing it to the PWM we published earlier for p53
(Supplementary Table S4) (28). The best performing p73
consensus motif based on the ROC, AUC is more degen-
erate than the previously identiﬁed p53 motif and clearly
shows a better performance for the p73 sequences
(Supplementary Figure S3). We used the algorithm
p53scan (28) with this PWM to scan all identiﬁed
binding sites for the new p73 consensus motif. For this
purpose, we grouped all binding sites into seven different
groups, according to which combinations of p53-family
proteins were recruited (Table 3). Subsequently, we
determined the fraction of sequences containing a p73
motif for each group (Figure 5B). In the p73 groups, we
ﬁnd that at least 70% of the sequences contain the p73
consensus motif. In contrast, the group of sequences
bound only by p53 has a low number of p73 consensus
motifs (20%). The score of the p73scan algorithm depends
on the conformity of the identiﬁed motif in a speciﬁc
sequence to the ideal consensus motif, the p73 motif in
this case. Interestingly, the median motif score for
TAp73a and p53 groups of binding sites is lower when
compared with groups containing TAp73b binding sites
(Figure 5C). The group with the highest score, i.e. with
the highest similarity to the ideal consensus p73 motif, is
the group of target sites bound by both p53 and TAp73b.
We conclude that the p53-family members have distinct
requirements toward their binding sites resulting in
Figure 4. Continued
The three lower tracks show the signals from RNA-seq for Saos2 parental cells or upon induction of either TAp73a or TAp73b. Below the tracks,
the respective gene is displayed. On the right the expression change of the respective gene upon TAp73a or TAp73b induction is validated by
RT-qPCR. SD was derived from three independent experiments. (D) Preferential binding of TAp73b results in speciﬁc transcriptional induction of
the BGN-gene by TAp73b.( E) The GRHL3-gene was bound by TAp73a and TAp73b and changes its expression upon induction of both isoforms.
(F) Correlation between association strength of TAp73a and TAp73b and expression changes. Non-regulated genes and genes regulated with an
absolute log2>1 are shown.
Table 2. Expression changes upon TAp73 induction
Total
number
of genes
Genes with a
binding site
within 25kb
P-value of overlap
between binding
and expression
change
Induced by TAp73a 344 170 3.08E-019
Repressed by TAp73a 477 100 9.99E-001
Induced by TAp73b 260 129 3.56E-007
Repressed by TAp73b 653 193 9.97E-001
Induced by p53 350 152 6.53E-010
Repressed by p53 305 66 9.97E-001
Nucleic Acids Research, 2011 9
 
a
t
 
S
t
a
d
t
 
u
n
d
 
U
n
i
v
e
r
s
i
t
a
t
s
b
i
b
i
o
t
h
e
k
 
/
 
S
e
c
t
i
o
n
 
M
e
d
i
z
i
n
i
s
c
h
e
 
H
a
u
p
t
b
i
b
l
i
o
t
h
e
k
 
o
n
 
A
u
g
u
s
t
 
1
3
,
 
2
0
1
1
n
a
r
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 AC
D
F E
G
B
Figure 5. Characteristics of TAp73a- and TAp73b binding sites. (A) The newly identiﬁed TAp73-binding motif visualized by WebLogo (56). (B) The
percentage of binding sites containing the p73 motif as determined by p73scan. Binding sites are divided in seven different groups based on detected
binding of TAp73a, TAp73b and/or p53: (i–iii) bound by only one family member, (iv) and (v) by p53 and either TAp73 isoform, (vi) by both TAp73
isoforms and (vii) by both TAp73 isoforms and p53. (C) Boxplot of the TAp73 motif scores, as determined by p73scan, of the groups described in
‘B’. (D) The AP1 sequence motif identiﬁed in the TAp73a binding sites visualized by WebLogo. (E) The percentage of binding sites containing the
AP1 motif of the groups described in ‘B’. (F) The location of the AP1 motif in TAp73a binding sites, relative to the peak summit. (G) Boxplot of the
log2-fold expression change (Saos cells expressing TAp73a or TAp73b versus Saos2 parental control) of the genes identiﬁed in Barenco et al. (43) to
be c-Jun/NF-kB dependent. Expression of TAp73a cells is shown in light grey, TAp73b is shown in dark grey. The difference in the median fold
change between TAp73a and TAp73b is signiﬁcant (P<0.001, Wilcoxon rank sum test).
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 speciﬁc motifs and that a p73 speciﬁc binding motif can be
extracted from our global analysis.
Besides the p73 motif itself, the AP1 motif (Figure 5D)
which can be bound by heterodimers of the Jun/Fos
family (42) is signiﬁcantly overrepresented in the se-
quences occupied by TAp73a (8.2 times, P<1E-10) and
in the TAp73a and p53 group (11.8 times, P<1E-10)
compared with a random set of background sequences
(Figure 5E). Strikingly, whereas this motif is found in
24–35% of the sequences in sites bound by TAp73a or
TAp73a and p53, it is not enriched in the TAp73b or
the p53 and TAp73b sites. The location of the AP1
motif is plotted relative to the TAp73a peak summit in
Figure 5F. The distinct centered distribution indicates that
the AP1 motif is located in very close proximity to the
actual TAp73a binding site. A similar distribution is
also seen for the distance between TAp73b or p53 peak
summits and occurring AP1 motifs, although the
frequencies of AP1 motif occurrences are lower
(Supplementary Figure S4A). While the AP1 and p73
motifs occur close together, there does not seem to be a
speciﬁc ﬁxed distance (Supplementary Figure S4B).
The relationship between TAp73a and transcription
factors binding to AP1 sites was further strengthened
when we assessed putative AP1 target genes. Recently, a
group of genes predicted to be controlled by c-Jun/NF-JB
was identiﬁed (43). Of those genes, 20% overlap with the
genes differentially regulated by TAp73a and TAp73b
(P<0.0001). Strikingly, the median log2 fold expression
change for these genes in TAp73a cells is 0.36, while these
genes have a median log2 fold change of  0.41 (P<0.001)
in TAp73b cells (Figure 5G). In TAp73a-expressing cells,
genes with an AP1 motif are more often upregulated
compared to genes lacking this motif (Supplementary
Figure S5 and Table S4). This correlation is not
observed for TAp73b.
In conclusion, the sequences of the identiﬁed p73
binding sites show clear isoform-speciﬁc characteristics.
In particular, the overrepresentation of the AP1 motif
distinguishes the TAp73a from the TAp73b binding sites.
TAp73a activates genes containing an AP1 motif close
to a p73 binding site
The transcription factors of the AP1 family regulate many
growth-related functions; therefore, we wondered whether
genes assigned to p73 binding sites co-occurring with AP1
motifs could contribute to the physiological differences we
observed between TAp73a and TAp73b. We chose ﬁve
genes in which an AP1 motif is also present and
detected strong enrichment of TAp73a at all tested
binding sites, while the binding of TAp73b is not signiﬁ-
cantly enriched (Figure 6A). Next, we assessed whether
c-Jun is differentially recruited in the presence or
absence of either TAp73a or TAp73b. ChIP-qPCR of
c-Jun revealed clear binding of c-Jun to target sites in
parental Saos2 and in TAp73a-expressing cells
(Figure 6B). In the cases of NEDD4L and RNF43, the
expression of TAp73a increases the binding of c-Jun,
compared with parental Saos2 cells. Importantly, in
TAp73b expressing cells c-Jun binding to the respective
target sites is reduced compared with parental Saos2
cells. We also analyzed whether p53 was bound to these
AP1 motif-containing sites and whether it could change
the recruitment of c-Jun. While strong binding of p53 was
not observed, the binding of c-Jun to these sites appears to
remain unchanged in p53-expressing cells compared with
parental Saos2 cells (Supplementary Figure S6). To
validate that TAp73a and c-Jun are actually bound sim-
ultaneously to the same binding regions, we performed
ChIP-re-ChIP analysis. For all tested target genes, we
could re-ChIP c-Jun at the TAp73a-bound target sites
and vice versa, showing that TAp73a and c-Jun can
indeed be found on the same binding regions at the
same time (Figure 6C and Supplementary Figure S7).
In concordance with the binding data, TAp73a induces
the mRNA expression of all ﬁve genes (Figure 6D).
Surprisingly, we found a repression of the level of
mRNA of the same genes upon TAp73b induction, in
the case of RNF43 or IL1RAP a substantial decrease to
5–10% of the level of expression in the parental Saos2
cells. To show the dependence of these target genes from
endogenous p73 and c-Jun, we silenced the expression of
p73 and c-Jun in HCT116 and MDA-MB231 cells, re-
spectively, and analyzed the expression of NEDD4L,
IL1RAP and CDK6 (Figure 6E and F). The reduction
of p73 levels leads to a small decrease of NEDD4L- and
CDK6-mRNA and a strong reduction of the IL1RAP ex-
pression (Figure 6E). After the reduction of c-Jun expres-
sion, the mRNA levels of all three tested genes were
reduced more than 30% (Figure 6F).
To further explore the relationship between c-Jun and
p73, we analyzed the levels of c-Jun mRNA in
TAp73b-expressing cells (Figure 6G, left). Strikingly,
upon TAp73b induction the c-Jun mRNA level is
strongly reduced, an effect also seen in our RNA-seq
data (Supplementary Figure 2C). The protein level of
c-Jun is also reduced speciﬁcally upon TAp73b induction,
while neither TAp73a nor p53 exert a similar effect
(Figure 6G, right).
Thus, we have identiﬁed a speciﬁc set of TAp73a target
sites that also contain an AP1 site and that are bound by
c-Jun. Very interestingly, these AP1 motif-containing
target sites are not bound by TAp73b. Furthermore,
while the endogenous expression of these genes seems to
depend on p73 and c-Jun, a repression of the associated
genes speciﬁcally upon TAp73b induction is observed, at
least partly due to a negative regulation of c-Jun by
TAp73b. Thus, the interplay between c-Jun and TAp73
Table 3. Groups of p53-family speciﬁc genes
Genes bound by different family members Number of
binding sites
TAp73a only 4196
TAp73b only 11849
p53 only 4009
p53+TAp73a 4532
p53+TAp73b 5091
TAp73a+TAp73b 10319
p53+TAp73a+TAp73b 3754
Nucleic Acids Research, 2011 11
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Figure 6. Opposite effects of TAp73a and TAp73b on target genes close to an AP1 motif. (A) TAp73a but not TAp73b binds to AP1
motif-containing binding sites. ChIP-qPCR was performed in Saos cells expressing TAp73a or TAp73b for 24h, with primers covering putative
AP1 binding sites. SD was derived from three independent experiments. (B) Binding of c-Jun to putative target genes is reduced in
TAp73b-expressing cells. ChIP-qPCR of c-Jun was performed in Saos2 cells, either the parental cell line, or cells expressing TAp73a or TAp73b
for 24h. Same primers as in ‘A’ were used and SD was derived from three independent experiments. (C) ChIP-re-ChIP shows binding of TAp73a and
c-Jun to the same sites on DNA. After induction of TAp73a chromatin complexes were precipitated ﬁrst with a p73-antibody. After elution a second
12 Nucleic AcidsResearch, 2011
 
a
t
 
S
t
a
d
t
 
u
n
d
 
U
n
i
v
e
r
s
i
t
a
t
s
b
i
b
i
o
t
h
e
k
 
/
 
S
e
c
t
i
o
n
 
M
e
d
i
z
i
n
i
s
c
h
e
 
H
a
u
p
t
b
i
b
l
i
o
t
h
e
k
 
o
n
 
A
u
g
u
s
t
 
1
3
,
 
2
0
1
1
n
a
r
.
o
x
f
o
r
d
j
o
u
r
n
a
l
s
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 is isoform dependent, leading to differential binding of
c-Jun to its target genes and to a differential transcription-
al outcome.
The TAp73a-target genes IL1RAP and NEDD4L can
inﬂuence apoptosis
Several of the genes that are in close proximity to
combined TAp73a/AP1 binding sites are linked to tumori-
genesis or malignant growth (Table 4). Because TAp73a
can induce these genes, we assessed whether these target
genes impede on the induction of programmed cell death.
To this end, we overexpressed two of these gene products,
NEDD4L and IL1RAP, in Saos cells inducible for
TAp73a. The effect of the overexpressed proteins on the
TAp73a induced apoptosis was monitored by staining for
active Caspase3. TAp73a induces the cleavage of
Caspase3 mainly after 48h (Figure 7A). Upon transfec-
tion of IL1RAP, the amount of activated Caspase3 is
markedly decreased, especially after 48h of TAp73a in-
duction. NEDD4L impedes on the accumulation of active
Caspase3 in a similar way, mainly after 48h of TAp73a
induction. To examine the physiological role of IL1RAP
and NEDD4L in the TAp73a-signaling pathway, we
transfected siRNAs directed against IL1RAP and
NEDD4L into TAp73a-expressing cells. Analysis of the
mRNA after transfection of the respective siRNA and
induction of TAp73a for 24h shows that the knockdown
of IL1RAP and NEDD4L has an efﬁciency of at least
80% (Figure 7B). Strikingly, the knockdown of IL1RAP
and NEDD4L increases the induction of active Caspase3
after 24 and 48h of TAp73a induction (Figure 7C, left).
Analyzing the population of cells in sub-G1, we found
that the knockdowns lead to a statistically signiﬁcant
increase of TAp73a-induced apoptosis (Figure 7C,
right). Thus, we have identiﬁed two target genes of
TAp73a that seem to impede on the apoptosis induction
capability of TAp73a, most likely via a pathway involving
c-Jun.
We propose that the differences in apoptosis induction
by TAp73a and TAp73b are mediated at least partly by
the differential collaboration with c-Jun: in the case of
TAp73a AP1 binding sites are bound by c-Jun and the
respective proliferation related target genes are induced
leading to a weaker apoptotic response of TAp73a.O n
the other hand the TAp73b binding sites are not only
devoid of AP1 sites, but TAp73b negatively regulates the
c-Jun levels leading to much less c-Jun being bound at the
respective AP1 sites which ultimately results in much
higher levels of apoptosis.
DISCUSSION
A marked physiological difference between the two most
commonly expressed TAp73 isoforms, TAp73a and
TAp73b has been reported (16,44), but the molecular
mechanism for the observed different cellular response
upon TAp73a and TAp73b activation has remained
elusive. Here, we analyze the differences of TAp73a and
TAp73b target gene binding and regulation and propose
that the balance between survival and apoptosis induction
Figure 6. Continued
round of immunoprecipitation was performed with a c-Jun- or again with a p73-antibody. The second ChIP included an unspeciﬁc antibody control
to calculate enrichment. SD was derived from three independent experiments. (D) Opposite regulation of AP1 motif-containing target genes by
TAp73a and TAp73b. Changes in expression of mRNA of the target genes from ‘A’, upon induction of TAp73a or TAp73b for 24h. SD was
calculated from three independent experiments. (E) Expression of AP1 motif-containing target genes is reduced after knockdown of p73. After
knockdown of p73 in HCT116 cells, protein levels of p73 (left) or transcriptional levels of the respective target genes (right) were analyzed. Error bars
were derived from two independent experiments. (F) Knockdown of c-Jun reduces the expression of AP1 motif-containing target genes. After
knockdown of c-Jun in MDA-MB231 cells, protein levels of c-Jun (left) or transcriptional levels of the respective target genes (right) were
analyzed. Error bars were derived from two independent experiments. (G) The c-Jun expression levels are downregulated by TAp73b. Expression
of c-Jun mRNA upon induction of TAp73a, TAp73b or p53 for 24h (left). SD was calculated from three independent experiments. Protein-levels of
c-Jun were analyzed in Saos cells after induction of TAp73a, TAp73b or p53 for 24h before whole cell extract was isolated and the indicated proteins
were stained by western blot (right).
Table 4. Known function of TAp73a target genes with an AP1 motif
Gene name Known function Reference
RNF43 Upregulated in colorectal cancers; growth promoting if exogenously expressed (47,57)
NEDD4L Na
+ channel regulation/tumor associated via Wnt-signaling in liver cancer/neuronal survival via Trk
neurotrophin receptors
(58,59)
CDK6 Catalytic subunit for G1/S transition/stimulates growth in prostate cancer/overexpressed in medullablastoma;
poor prognosis marker
(46,60)
IL1RAP Involved in IL1 action during inﬂammation/activation of NFkB pathway (61,62)
PAI-1 Promoter of tumor progression/poor prognosis marker (63–66)
RIPK4 Can activate NFkappaB/processed during apoptosis/involved in differentiation (67,68)
GAP43 Growth associated protein 43/highly expressed during neuronal development and axonal regeneration/neurite
outgrowth/AP1& TrkA associated
(69)
SDC1 Participates in cell proliferation, cell migration and cell-matrix interactions/Altered (higher) syndecan-1
expression has been detected in several different tumor types
(70,71)
NGFR Tumor suppressor in retinoblastoma/necessary for cell survival in ESCC/Inducer of apoptosis in absence of
ligand/Interaction with TrkA/critical regulator of glioma invasion
(72–75)
Nucleic Acids Research, 2011 13
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 by TAp73a and TAp73b is mediated at least partly by the
differential interplay with c-Jun. In our global binding site
analysis, we identiﬁed a consensus binding motif for
TAp73a and TAp73b. Although this motif resembles the
previously described p53 consensus motif (28), it has
several distinct features, e.g. the bases outside the four
nucleotide core are less preserved and it is thereby closer
related to the binding motif described for p63 (45).
Assessing the molecular differences between TAp73a
and TAp73b, we found that an AP1 motif is strongly
enriched in the region surrounding many binding sites of
TAp73a, but not in TAp73b binding sites. We observed a
striking difference in the expression of the target genes
with an AP1 motif in the TAp73a- versus TAp73b-
expressing cells. While these target genes are selectively
bound by TAp73a together with c-Jun and subsequently
upregulated, TAp73b represses their mRNA expression.
In line with these ﬁndings, we observed that the
recruitment of c-Jun to the AP1 sites of these genes is
impaired upon TAp73b induction probably caused by a
downregulation of c-Jun mRNA and protein by TAp73b.
Several of the assigned target genes are related to malig-
nant growth, like CDK6 and RNF43 (46,47). We show
that two genes speciﬁcally upregulated in TAp73a-
expressing cells, NEDD4L and IL1RAP, are able to inﬂu-
ence the induction of apoptosis upon their overexpression
or siRNA-mediated downregulation, thereby showing
that TAp73a indeed induces antiapoptotic factors.
Analysis of TAp73a and TAp73b transcriptional activities
It has been reported previously that TAp73b can induce
the expression of p53-target genes like p21 or Mdm2 to a
higher extent than TAp73a (15,48,49), while also
TAp73a-speciﬁc target genes have been reported (50).
Furthermore, TAp73b has been described to be a much
A
TAp73α
NEDD4L
IL1RAP
Caspase3
TBP
TAp73α induction:           24 hr        48 hr      
Vector control        +                       + 
FLAG-IL1RAP        +                     +
FLAG-NEDD4L       +            +
B
Knockdown in Saos TAp73α cells
0%
20%
40%
60%
80%
100%
120%
control IL1RAP NEDD4L
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TAp73α
Caspase3
TBP
siRNA:
TAp73α induction: 
C
IL1RAP siRNA
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control siRNA
Induction of apoptosis TAp73α induction:           24 hr       48 hr      
control siRNA    +                     + 
IL1RAP siRNA        +                     +
NEDD4L siRNA     +            +
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Figure 7. Target genes of TAp73a and c-Jun impede on apoptosis induction. (A) Overexpression of IL1RAP, NEDD4L or an empty vector in Saos
cells expressing TAp73a. After induction for 24 or 48h whole cell extracts were analyzed by western blot. (B) Knockdown of IL1RAP and
NEDD4L. TAp73a-expressing Saos cells were transfected twice with a pool of four different siRNAs against each gene or a non-targeting
siRNA-pool. After induction for 24h mRNA was harvested and the efﬁciency of knockdown was monitored setting the non-targeting sample to
100%. Error bars result from two biological replicas. (C) Knockdown of IL1RAP and NEDD4L increases apoptosis. TAp73a-expressing Saos cells
were transfected as in ‘B’, prior to isolation of whole cell extract and western blot analysis (left panel) or preparation for FACS analysis to determine
the amount of cells in sub-G1 phase as a measure for apoptotic induction (right). Asterisks indicates P<0.05. SD was derived from three inde-
pendent experiments.
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 stronger inducer of apoptosis (51,52). In line with this, our
data show that known target genes like Mdm2 and p21 are
bound with higher afﬁnity and induced to higher levels
through TAp73b and that the induction of apoptosis by
TAp73b is much stronger. Nevertheless, our study now
extends previous analysis by combining ChIP-seq and
RNA-seq to compare these two most prevalent TAp73
isoforms with each other as well as with p53 with
respect to global target gene binding and expression.
Strikingly, besides common target genes bound and
regulated by TAp73a, TAp73b and p53, we found target
genes that were regulated in an isoform-speciﬁc manner.
In summary, our data provide a genome-wide analysis of
TAp73a, TAp73b and p53 chromatin occupancy and the
correlation thereof with transcriptional changes upon
TAp73a, TAp73b and p53 induction. This enables a
careful examination of the isoform speciﬁc as well as
overlapping target genes and provides a basis for further
functional characterization.
Isoform-speciﬁc functional interplay of TAp73 with c-Jun
Our data show that the cellular outcome of the interplay
between c-Jun and p73 depends on the presence of the
respective TAp73 isoform. First, our motif analysis of
genome-wide data showed a striking co-occurrence of
c-Jun-binding motifs with TAp73a binding sites, to
which both proteins bind simultaneously. Second, induc-
tion of TAp73b resulted in a reduction of c-Jun mRNA
and protein levels and hence to a lack of recruitment of
c-Jun. Third, there is a positive correlation between
TAp73a-induced genes and c-Jun target genes, while this
correlation is inversed for TAp73b-regulated genes. Thus,
the poor induction of cell death by TAp73a could be due
to activation of antiapoptotic target genes along with
c-Jun, while the stronger apoptosis induced by TAp73b
is caused at least partly by a reduction of cellular c-Jun
levels and subsequent reduced recruitment of c-Jun to
DNA resulting in repression of these target genes.
Several of these target genes are linked to malignant
growth and their mRNA levels were induced by TAp73a
but repressed by TAp73b. The negative regulation of
genes related to proliferation by TAp73b and p53 that
was reported earlier (53) might, therefore, also be
extended to these AP1 motif-containing genes. This AP1
motif can be bound by c-Jun, which has been reported to
stabilize p73 and thereby to enhance its function, although
no direct interaction was observed (22). More recently, it
was reported that c-Jun plays an important role in apop-
tosis induced by chemotherapeutic treatments mediated
by YAP1, a critical regulator of p73 (54,55). On the
other hand, c-Jun and p73 have also been shown to
co-operate during growth promotion and to synergistical-
ly induce transcription from c-Jun response element con-
taining promoter constructs in the absence of additional
apoptosis-inducing treatments (21). Based on our ﬁndings,
we speculate that the differences in cellular outcome are
due to the presence of the particular TAp73 isoform in the
respective cellular system and its respective interplay with
c-Jun which appears to be cell type dependent. The weaker
induction of cell death by TAp73a that we observed in our
experimental system might, therefore, be mediated by the
activation of antiapoptotic target genes together with
c-Jun, while the stronger apoptosis induced by TAp73b
might be due to the repression of these target genes and
a reduction of c-Jun levels. The cell-type, treatment- and
isoform-speciﬁc differences inﬂuencing the cellular fate
hint toward several layers of regulation between p73 and
c-Jun and might be a very important molecular explan-
ation for the different observed phenotypes induced by the
TAp73 isoforms.
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